The most common articular pathology is osteoarthrosis of the knee joints. More than 10 % of the world's population suffers from this disease. The development of osteoarthrosis (OA) is also affected by metabolic syndrome (MS), which is characterized by abdominal obesity, dyslipidemia, arterial hypertension and disturbance of carbohydrate metabolism. The combination of MS and osteoarthrosis creates conditions of overload for the functioning of axial joints, which is one of the main causes of premature disability and invalidization of the population. Treatment of OA of the knee joints in women in the menopausal period with concomitant metabolic syndrome presents great difficulties. To achieve a stable result of treatment, therapy with chondroprotectors and nonsteroidal anti-inflammatory drugs (NSAIDs) is used. Treatment was carried out in 60 women in the menopausal period with MS, suffering from OA of knee joints. In the group of women in the menopausal period with OA of knee joints and MS who took therapy with the inclusion of the soybean and avocado drug alongside with NSAIDs, a significant effect was obtained with regard to arresting the pain syndrome, improving the quality of life, reducing the degree of inflammation as well as increased joint mobility compared with the group of patients, who took only chondroprotectors and NSAIDs

Приведены результаты психологического исследования влияния препарата Дилепта® на когнитивные функции у больных малопрогредиентной шизофренией, являющегося фрагментом пилотного изучения нового препарата пептидной природы в качестве антипсихотического средства (II фаза), обладающего по экспериментальным данным положительным влиянием на когнитивные функции. Исследование проведено на выборке из 25 пациентов, средний возраст (33,4 ± 10,0) лет, с диагнозом псевдоневротической шизофрении (F21.3 по МКБ-10) без сопутствующих психических и соматических расстройств. Когнитивные функции оценивали с использованием теста Векслера (WAIS). Контрольную группу составили 70 здоровых испытуемых, средний возраст (30,2 ± 8,1) лет. При поиске терапевтически эффективной дозы препарата по 5 пациентов получали дилепт в дозах 60 и 120 мг/сут, 15 — в дозе 200 мг/сут. Длительность терапии Дилептом® составляла 28 дней. В соответствии с протоколом исследования при недостаточной эффективности дилепта, усилении тревоги и нарушениях сна 19 пациентов с 15 дня терапии получали феназепам (0,5 – 2 мг/сут). Установлено достоверное снижение большинства показателей теста WAIS у исследованных больных, по сравнению со здоровыми испытуемыми. Показано независимое от действия феназепама более значительное позитивное изменение разных параметров когнитивного функционирования при применении дилепта в терапевтически эффективной дозе 200 мг/сут по сравнению с дозами 60 и 120 мг/сут, проявляющееся в улучшении скорости психомоторных реакций, внимания, памяти, мышления, социальных когнитивных функций. По результатам психологических исследований установлено наличие у дилепта антипсихотического, психостимулирующего и прокогнитивного действия.

Objective. To study the effectiveness of the preoperative combined correction, using hydroxide of iron (III) and stimulation of hematopoiesis with erythropoietin on the postoperative anemia in patients, undergoning bloodless surgery (mitral valvere placement) in conditions of artificialblood circulation. Methods. A single-center prospective non-randomized and retrospective study involving patients (n=80) undergoning the operation for mitral valve disease was carried out. There were 54 men (67.5%) and 26 women (32.5%) with an average age of 52.8±4.9 years (M±σ). The patients were divided into three groups. Group A consisted of patients with normal serum iron levels undergoning of the application of blood component preparations. Group B included patients with normal serum iron levels who were undergoning bloodless surgery. In group C the patients with initially low levels of iron in the blood serum, preoperative correction of the saturating dose iron hydroxide and stimulation with erythropoietin were carried out, and bloodless procedure was applied while the operation. Results. The results of this study show that patients in group A require a sufficiently large volume of donor blood components during surgery. In group B, mitral valve replacement can be performed using bloodless technology without transfusion of donor blood components. Correction of a low preoperative serum iron level in group C increases its preoperative serum iron level by 7.4 times and Hb by 4.4% of the initial haemoglobin values. The level of postoperative anemia in group C (p>0.05) compared with group B (p>0.05) is 8.5% less (p>0.05). Conclusion. Correction of low preoperative iron levels and stimulation of erythropoiesis in patients with mitral heart disease after mitral valve replacement using a bloodless surgery reduces the postoperative anemia level. What this paper adds For the first time the impact of preoperative correction of anemia, using iron (III) hydroxide and stimulation of hematopoiesis, applying erythropoietin in patients undergoning the surgery for mitral valve defect using bloodless technology in conditions of artificial blood circulation (ABC) has been determined.

The article is dedicated to the optimization of the treatment of postoperative anemia in patients with mitral and aortic valve replacement through blood saving technology (BST). The aim. To investigate the preoperative combined effect of iron (III) hydroxide and erythropoietin on the level of postoperative anemia after mitral and aortic valve replacement (MAVR) through BST in the conditions of artificial circulation. Material and methods. Preoperative levels of Hb, Ht, iron, and enzymes were studied in 53 patients with com-bined mitral and aortic heart defects. All the patients are divided into groups A, B, C. Patients with normal levels of Hb, Ht, RBC, iron were divided into groups A and B. Patients of group A were operated with the use of donor blood components, and in group B - no donor blood components were used. In group C where the patients had low iron values, preoperative iron correction and erythropoietin stimulation were performed. Operations in group C were performed using BST. Results. According to the study results, the patients of group A needed sufficient volume components of donor blood (621.0 ± 103.0 ml of red cell mass and 713.0 ± 89.0 ml of fresh-frozen plasma) in the operative period. MAVR with BST in group B was possible without transfusion of donor blood preparations, however, Hb decrease by 17.1% dictated the need for preoperative preparation of donor blood components. Correction of low levels of preoperative serum iron in group C resulted in its 8.9-fold rise compared to the pre-operative level, as well as Hb increase by 5.8%. The use of BST during MAVR reduces postoperative anemia by 7.7% and helps to avoid transfusion of donor blood components. Conclusions. Correction of low preoperative levels of iron and erythropoietin in patients with mitral and aortic heart defects reduces the level of postoperative anemia after operations with mitral and aortic valve replacement through BST.